<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597437</url>
  </required_header>
  <id_info>
    <org_study_id>NCR203024</org_study_id>
    <nct_id>NCT04597437</nct_id>
  </id_info>
  <brief_title>Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)</brief_title>
  <acronym>ZAP-DENGUE</acronym>
  <official_title>Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naval Medical Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infantil de Niño Jesús de Barranquilla (HINJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Bosque</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allied Research Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety&#xD;
      and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability&#xD;
      syndrome which is the main cause of death in dengue fever.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety&#xD;
      and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability&#xD;
      syndrome which is the main cause of death in dengue fever. Our central hypothesis is that&#xD;
      zanamivir treatment is safe in patients with dengue infection, will significantly decrease&#xD;
      serum sialic acid levels, and will result in fewer patients with the development of moderate&#xD;
      or severe clinical plasma leakage. 74 male and non-pregnant female volunteers age 7 years and&#xD;
      older from Colombia with a diagnosis of dengue fever with warning signs or severe dengue as&#xD;
      per the World Health Organization 2009 definition with the presence of fever and positive&#xD;
      rapid test for the presence of dengue non-structural protein-1 (NS1) will be randomized to&#xD;
      zanamivir versus placebo. In the treatment group, participants will receive 600 mg for adults&#xD;
      and 12 mg/kg in children intravenously every twelve hours for 5 days adjusted for renal&#xD;
      function. In the placebo group, participants will receive placebo normal saline solution&#xD;
      intravenously every twelve hours for 5 days.&#xD;
&#xD;
      All patients will receive blood draws for assessment of hematocrit, renal function, and&#xD;
      biologic efficacy endpoints and clinical evaluation of signs and symptoms of vascular&#xD;
      permeability (which may include ultrasound and radiograph) and adverse events daily during&#xD;
      the five days of medication administration and once at follow up at 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pilot, randomized, double-blind, placebo-controlled trial of the safety and efficacy of inhaled zanamivir (n=37) versus placebo (n=37) therapy for dengue</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events of intravenous zanamivir treatment versus placebo in dengue</measure>
    <time_frame>Over 14 days</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events will be assessed by daily active surveillance during drug administration and at 2-week follow-up as per the United States Food and Drug Administration guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of endothelial glycocalyx biomarkers in intravenous zanamivir treatment versus placebo in dengue</measure>
    <time_frame>Over 14 days</time_frame>
    <description>Serum concentration of key endothelial glycocalyx components due to endothelial damage such as sialic acid, heparan sulfate, and syndecan-1 will be assessed by ELISA.&#xD;
Serum concentration of sialidases (NEU2 and NEU3) that are directly inhibited by zanamivir will be assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary clinical efficacy of intravenous zanamivir treatment versus placebo in dengue</measure>
    <time_frame>Over 14 days</time_frame>
    <description>Presence of moderate or severe plasma leakage as defined by the Standard Clinical Endpoints for Use in Dengue Interventional Trials where moderate plasma leakage is defined as 15% change in hematocrit or evidence of fluid on ultrasound or X-ray and severe plasma leakage is defined at the presence of shock or respiratory compromise with evidence of plasma leakage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Zanamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the treatment group, participants will receive 600 mg for adults and 12 mg/kg in children intravenously every twelve hours for 5 days adjusted for renal function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanamivir</intervention_name>
    <description>Intravenous zanamivir</description>
    <arm_group_label>Zanamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form.&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
          3. Male or female, aged &gt;7 years&#xD;
&#xD;
          4. Willingness to receive intravenous medication and be willing to adhere to the&#xD;
             medication regimen&#xD;
&#xD;
          5. Have a diagnosis of dengue by dengue NS1 rapid test&#xD;
&#xD;
          6. Have had a documented fever &gt;38C in the last 24 hours.&#xD;
&#xD;
          7. Have dengue with warning signs as per the 2009 WHO criteria including one of the&#xD;
             following: abdominal pain or tenderness, persistent vomiting, clinical fluid&#xD;
             accumulation, mucosal bleeding, lethargy, restlessness, liver enlargement over 2 cm,&#xD;
             augmented hematocrit, thrombocytopenia or severe dengue defined as dengue with severe&#xD;
             plasma leakage leading to dengue shock and/or fluid accumulation with respiratory&#xD;
             distress; severe hemorrhage; severe organ impairment (hepatic damage, renal&#xD;
             impairment, cardiomyopathy, encephalopathy or encephalitis).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Children in Care of the state&#xD;
&#xD;
          3. Patients who are unlikely to survive 48 hours&#xD;
&#xD;
          4. Elevated alanine aminotransferase ≥3 times the upper limit of normal (ULN)&#xD;
&#xD;
          5. Total bilirubin ≥2 × ULN&#xD;
&#xD;
          6. Unstable cardiac disease or arrhythmia at baseline&#xD;
&#xD;
          7. History of significant cardiac disease&#xD;
&#xD;
          8. Treatment with another investigational drug or other intervention within 1 month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aileen Y Chang, MD</last_name>
    <phone>202-741-6562</phone>
    <email>chang@email.gwu.edu</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified information can be shared with other investigators. Please contact Dr. Aileen Chang at chang@email.gwu.edu</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

